Ionis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good afternoon, and welcome to the 19th Annual Morgan Stanley Healthcare Conference. Before I get started, let me just go through the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions)
And with that, I'm David Lebowitz, one of the biotechnology analysts here. And I'm happy to have with me from Ionis, CFO, Beth Hougen. Clearly, Ionis is one of the leaders in RNA medicine. Specifically, they have developed antisense technology and have a very, very large clinical pipeline of -- clinical-stage pipeline, over 40 drugs actually in the clinic at this point.
And I guess, Beth, if you could start off just by telling me a little bit about the history of the company, some of the recent transition and strategically, what is Ionis looking to do going forward.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |